No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study.
about
HLA-B27-associated reactive arthritis: pathogenetic and clinical considerationsPersistent Chlamydiae and chronic arthritisPersistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitroCombination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial.Immunological basis of Chlamydia induced reactive arthritis.Reactive arthritis and Reiter's syndrome following an outbreak of gastroenteritis caused by Salmonella enteritidis.Nontyphoidal salmonellosis.Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays.Combination antibiotics for the treatment of Chlamydia-induced reactive arthritis: is a cure in sight?Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis.Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritisFrequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis.Comparison of rheumatological and gastrointestinal symptoms after infection with Campylobacter jejuni/coli and enterotoxigenic Escherichia coliAntibiotic treatment and long term prognosis of reactive arthritisEffect of a three month course of ciprofloxacin on the late prognosis of reactive arthritisThree month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled studyManagement of reactive arthritis.Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial.Available options in the management of non-typhi Salmonella.Antibiotic treatment of Lyme borreliosis: what is the evidence?Pharmacological management of undifferentiated spondyloarthropathies.When is arthritis reactive?The molecular basis for disease phenotype in chronic Chlamydia-induced arthritis.Recent advances and future directions in understanding and treating Chlamydia-induced reactive arthritis.[Infection-induced reactive arthritis : etiopathogenesis, clinical spectrum, therapy].Double-blind, randomized, placebo-controlled study of three-month treatment with the combination of ofloxacin and roxithromycin in recent-onset reactive arthritis.Treating reactive arthritis: insights for the clinician.Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).Combination antibiotics for Chlamydia-induced arthritis: breakthrough to a cure?2014 European Guideline on the management of sexually acquired reactive arthritis.
P2860
Q24625587-68F6FD20-B0EC-4998-85D9-EE59C102A161Q24792605-B3655924-2F6A-4AD3-8C60-55043DBA207BQ33980950-E8720B93-F737-45DD-AAE5-A1CC2223976CQ34007328-2EF2D4E4-7BF3-4A3F-BF7A-637C59EB7D09Q34015063-7F99CBB2-33C9-4A4D-BE05-96D292AA2B5DQ34088734-2AF2117B-249A-4AB5-8D79-AE553221D0C1Q34136663-ABCF0490-672A-4452-AB46-7F42906BC3A4Q34526843-3005958C-416E-463D-B3BD-3FAE915C696AQ35163775-F83C3BAC-9B2E-497F-A967-3C5701F72939Q35549430-7EE870B8-52DD-4227-959F-999ABDB8492CQ35549974-7BE4D2DD-A86B-40AA-AEA5-506B31A2BA32Q35550301-116C3364-D580-4079-8CC6-20DC4C2C6699Q35551585-90CDC0C6-5838-4458-A5E8-F91E8AF210B6Q35552859-C21BE5B3-1EBA-4959-832F-35C4B25062D7Q35553062-AF59349C-A2C6-4A2B-A6E1-F1C69CFC7B1AQ35554555-A7175CA6-93A1-4AF2-A02A-BBA3F40BB84CQ35609680-4BB171C1-AD8E-4284-B645-6F601C5B93A2Q35638104-508D6A27-5B03-461A-ADB4-A2780423FE11Q35841582-528B08C9-7780-49FD-975F-DF318AB1B3DFQ36071885-ED42CE65-1F5D-452C-B8B3-D002F4AEBEAAQ36349645-F2FBC821-C0FC-408D-B48D-8978E5588108Q36528238-08C3EE88-07A2-4137-8039-45CACB1D5581Q36630577-72B1183F-0410-4963-91EF-4704AE674423Q37835700-8AA2D8DE-29FA-4E68-9576-819199039BEBQ37845350-C8B179DC-1745-47B7-A7A9-2CADD85A593BQ37846371-B4180875-B254-440D-83B4-11978344305AQ37853706-32FD5EB3-6C0F-4B99-86F1-60A9ECDD538CQ38199786-04114FCF-19C1-4E98-8768-14A025B1345FQ43413612-DFD2FD11-6084-4959-A956-4885E9523875Q53272760-A51342B2-7655-4414-839A-EA6B2EC7E0DA
P2860
No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1999
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
No benefit of long-term ciprof ...... zed, placebo-controlled study.
@en
No benefit of long-term ciprof ...... zed, placebo-controlled study.
@nl
type
label
No benefit of long-term ciprof ...... zed, placebo-controlled study.
@en
No benefit of long-term ciprof ...... zed, placebo-controlled study.
@nl
prefLabel
No benefit of long-term ciprof ...... zed, placebo-controlled study.
@en
No benefit of long-term ciprof ...... zed, placebo-controlled study.
@nl
P2093
P2860
P1476
No benefit of long-term ciprof ...... zed, placebo-controlled study.
@en
P2093
Granfors K
Gripenberg-Lerche C
P2860
P304
P356
10.1002/1529-0131(199907)42:7<1386::AID-ANR12>3.0.CO;2-E
P577
1999-07-01T00:00:00Z